Catalyst Pharmaceutical (CPRX) Q2 Earnings and Revenues Surpass Estimates

Group 1 - Catalyst Pharmaceutical (CPRX) reported quarterly earnings of $0.68 per share, exceeding the Zacks Consensus Estimate of $0.58 per share, and showing an increase from $0.56 per share a year ago, resulting in an earnings surprise of +17.24% [1] - The company achieved revenues of $146.56 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 5.30%, and up from $122.71 million in the same quarter last year [2] - Catalyst has consistently surpassed consensus EPS estimates for the last four quarters, indicating strong performance [2] Group 2 - The stock has gained approximately 6.5% since the beginning of the year, compared to the S&P 500's gain of 7.1%, suggesting a slight underperformance relative to the broader market [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The Zacks Rank for Catalyst is currently 2 (Buy), indicating expectations for the stock to outperform the market in the near future [6] Group 3 - The current consensus EPS estimate for the upcoming quarter is $0.56 on revenues of $138.29 million, while for the current fiscal year, the estimate is $2.25 on revenues of $559.96 million [7] - The Medical - Drugs industry, to which Catalyst belongs, is currently ranked in the top 34% of over 250 Zacks industries, suggesting a favorable industry outlook [8]